Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer

Maret L. Maliniak1†, Aswathy Miriam Cheriyan1,2†, Mark E. Sherman3, Yuan Liu4,5, Keerthi Gogineni5,6, Jiaqi Liu5, Jiabei He5, Uma Krishnamurti7, Jasmine Miller-Kleinhenz1, Ryan Ashiqueali1, Jinjing He5, Rami Yacoub1 and Lauren E. McCullough1,5*

Abstract

Background: Crown-like structures in breast adipose tissue (CLS-B), composed of necrotic adipocytes encircled by macrophages, are associated with obesity and hypothesized to worsen breast cancer prognosis; however, data are sparse, particularly in multi-racial populations.

Methods: We assessed specimens for CLS-B from 174 African-American and 168 White women with stage I–III breast cancer treated by mastectomy. Benign breast tissue from an uninvolved quadrant was immunohistochemically stained for CD68 to determine CLS-B presence and density (per cm² of adipose tissue). Demographic and lifestyle factors, collected via medical record review, were analyzed for associations with CLS-B using logistic regression. Multivariable Cox proportional hazards models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between CLS-B and overall (OS) or progression-free (PFS) survival.

Results: Detection of any CLS-B was similar between African-American (32%) and White (29%) patients with no evidence of an association between race and CLS-B in multivariable models (OR = 0.82, 95% CI = 0.49–1.36). Detection of CLS-B was associated with obesity (OR = 4.73, 95% CI = 2.48–9.01) and age ≥ 60 years at diagnosis (OR = 1.78, 95% CI = 0.99–3.21). There was some evidence of associations with parity and current smoking status. Detection of CLS-B was not associated with OS (HR = 1.02, 95% CI = 0.55–1.87) or PFS (HR = 0.99, 95% CI = 0.59–1.67).

Conclusions: Our results show a strong, positive association between BMI and CLS-B in non-tumor tissue similar to previous findings. Detection of CLS-B did not vary by race and was not associated with worse OS or PFS.

Keywords: Crown-like structures, Breast adipose tissue, Obesity, Progression-free survival, Breast cancer outcome disparity

* Correspondence: lauren.mccullough@emory.edu
M.L. Maliniak and A.M. Cheriyan are the co-first authors of this article.
† Maret L. Maliniak and Aswathy Miriam Cheriyan contributed equally to this work.
1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
5Winship Cancer Institute of Emory University, Atlanta, GA, USA
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Background**

Obesity is an established risk factor for postmenopausal breast cancer, notably hormone receptor-positive cancers [1, 2], and has been linked to a higher risk of recurrence and mortality regardless of menopausal and hormone receptor status [1, 3, 4]. Both systemic and local effects of obesity interact and contribute to the development and progression of breast cancer although mechanisms are not fully understood [1, 5]. Among postmenopausal women, adipose tissue is the main source of circulating estrogens, accounting for the link between obesity and increased breast cancer risk [6]. Obesity also results in chronic, subclinical inflammation characterized by elevated circulating pro-inflammatory mediators [7, 8] that have been linked to progression [9] and may increase risk via altered adipokine levels and insulin resistance [10]. Locally, adipocyte hypertrophy occurs in the breast of overweight/obese women that can lead to adipocyte death, resulting in macrophage recruitment and inflamed white adipose tissue (WAT) [11]. This adipocyte-macrophage interaction is characterized by the encirclement of necrotic adipocytes by macrophages in a crown-like pattern [11]. These crown-like structures in the breast adipose tissue (CLS-B) create a unique microenvironment rich in pro-inflammatory cytokines. Among women with breast cancer, CLS-B are associated with NF-κB activation, increased aromatase activity, and elevation of pro-inflammatory mediators, which may enhance invasiveness and metastatic potential [12–16].

Previous epidemiologic studies have consistently demonstrated a strong, positive association between obesity, typically measured using body mass index (BMI), and CLS-B [16–22], although CLS-B are also reportedly present in up to one third of lean women (BMI < 25 kg/m²). These data suggest that factors other than obesity contribute to the formation of CLS-B [23], but few studies have examined associations for other characteristics such as race/ethnicity, smoking status, and reproductive history. One previous study of 150 Black, non-Black Latinas, and Caucasian women with breast cancer found the highest numbers of CLS in the tumor tissue of Black patients and subsequently found CLS to be associated with lower survival; however, BMI was not available in this study [24]. Another analysis of CLS-B with survival included a low proportion of women with CLS-B and few clinical outcomes [25]. A case-only analysis of 127 patients who all developed metastatic breast cancer found that CLS-B was associated with shorter time to recurrence [19]. Thus, large epidemiologic studies with detailed clinical information in multi-racial populations are needed to assess determinants of CLS-B and their association with clinical outcomes.

Accordingly, we examined whether other patient factors, independent of BMI, are associated with detection of CLS-B in normal adjacent breast WAT tissue of cancer patients and whether CLS-B are associated with progression-free and overall survival in a large multi-racial study population. Given that African-American women have a higher prevalence of obesity than White women and higher rates of aggressive breast cancer subtypes and mortality, we were particularly focused on comparing the prevalence and clinical impact of CLS-B among African-American versus White women. Thus, we examined the detection of CLS-B in a study population with approximately equal numbers of African-American (n = 174) and White patients (n = 168) with stage I–III breast cancer diagnosed and treated at Emory University hospitals.

**Methods**

**Study population**

Women aged ≥18 years, diagnosed with primary invasive stage I–III breast cancer (ICD: C50) between January 1, 2007, and December 31, 2012, were identified via tumor registries associated with Emory University hospitals (n = 3173). Cases were initially screened and considered eligible if they were African-American or White, underwent mastectomy at an affiliated hospital, and had not received neoadjuvant treatment for their breast cancer or systemic therapy for the treatment of a previous cancer diagnosis (n = 648). Data abstractors further reviewed medical records for those passing initial screening and only included those meeting the above criteria upon review and clinical verification (n = 389). A further 47 patients were deemed ineligible upon specimen retrieval and staining due to unavailable tissue, inadequate adipose tissue for CLS scoring, or the presence of inflammation, tumor, or biopsy tract precluding accurate CLS-B assessment. Thus, 342 patients (n = 174 African-American, n = 168 White women) were included in final analyses (Fig. 1). Informed consent was provided by women undergoing mastectomy at Emory University hospitals. This study was approved by the Institutional Review Board of Emory University (00100602).

**Clinical data and biospecimen collection**

Demographic and clinical characteristics were systematically abstracted by research staff using REDCap (Research Electronic Data Capture) tools hosted at Emory University [26, 27] and included information such as age at diagnosis, lifestyle factors (e.g., smoking history, alcohol intake), gynecologic and reproductive history (e.g., age at menarche, number of live births, menstrual status), medical conditions, family history of breast cancer among first-degree relatives, tumor characteristics (stage, grade, hormone receptor status, number of positive
sentinel and axillary lymph nodes), and administered treatments. Independent data reviews were conducted for quality assurance. Menopausal status was categorized as premenopausal, perimenopausal, or postmenopausal based on clinical notes with women in the latter group exhibiting one of the following characteristics at the time of diagnosis: (1) having had bilateral oophorectomy, (2) reporting permanent cessation of menses for 12 or more months in the absence of chemotherapy or endocrine therapy, or (3) age > 55 years at diagnosis if data were missing. BMI was calculated using height and weight recorded prior to surgery (measured continuously as well as using cut-points based on World Health Organization (WHO) definitions: BMI < 25 kg/m² [under or ideal weight], BMI 25–29.9 kg/m² [overweight], or BMI ≥ 30 kg/m² [obese]) [28]. Tumors were classified as estrogen receptor (ER) and/or progesterone receptor (PR) positive if > 1% staining by immunohistochemistry (IHC) was reported clinically.

Non-tumor containing breast WAT specimens were obtained under a standard tissue acquisition protocol. For each participant, up to three formalin-fixed, paraffin-embedded (FFPE) blocks of normal adjacent breast tissue from quadrants uninvolved by cancer were selected. Specimens were examined with hematoxylin and eosin (H&E) staining by a pathologist (AMC, UK, MES) to ensure samples were representative of benign breast tissue. Blocks with the greatest area of fat and no evidence of biopsy tract change, fat necrosis, or increased inflammation were chosen to ensure the selection of the one best WAT enriched block per patient.

**Tissue and CLS-B assessment**

To evaluate the presence of CLS-B, consistent with previously established methods [21], deparaffinized, rehydrated sections obtained from selected FFPE blocks were stained for CD68 using IHC (Dako Envision (Dako) automated system for detection of CD68; 1:200 dilution, monoclonal mouse anti-human CD68 clone KP1, M0814, DAKO, Denmark) at Winship Cancer Institute’s Pathology Core Laboratory (Emory University). From the corresponding tissue blocks, unstained tissue sections were sequentially cut within an estimated 100 to 200 μm of the original H&E-stained section. Whole slide digital images of anti-CD68-immunostained slides were captured with the 3DHISTECH Panoramic Scanner 150 and images analyzed using Panoramic Viewer 1.15.4 (3DHISTECH Ltd., Budapest, Hungary). Adipose tissue areas were defined as those containing ≥ 75% adipose, and total breast WAT area (cm²) was determined as the product of total fat percentage (visually estimated) and the total tissue area on the slide measured with 3DHISTECH software. The presence and number of CLS-B were assessed within the observed fat area on the whole tissue slide, and each CLS-B was manually counted and annotated on the digital image. Each CLS-B was defined according to the proportion of adipocyte encirclement by CD68-positive macrophages as 50 to < 75%, 75 to < 90%, and ≥ 90% (Fig. 2a–c). In the primary analyses, the presence of CLS-B (yes, no) was defined as detection of any CLS-B with ≥ 50% adipocyte encirclement. In supplementary analyses, we examined associations with any

| Tumor and WAT specimen evaluation | N excluded (initial screening, clinical review) |
|----------------------------------|-----------------------------------------------|
| 137, 6                           | Race not African-American or White             |
| 552, 1                           | Surgery performed outside Emory hospitals     |
| 848, 70                          | Neoadjuvant chemotherapy/previous systemic therapy |
| 931, 16                          | Breast surgery not a mastectomy               |
| 30, 41                           | Duplicate records                             |
| 28, 125                          | Other (cancer history, insufficient information, metastasis) |

**Fig. 1** Flow chart illustrating patient selection and tissue availability.
CLS-B detected using ≥75% and ≥90% adipocyte encirclement to classify presence. Reviewers were masked to clinicopathological data and outcomes at the time of scoring. CD68 and CLS-B were visually assessed by a single reviewer (AMC) with validation of a subset \( n = 80 \) by two independent pathologists (UK and MES), with a Kappa score > 0.75 for both two-way comparisons. CLS-B density, quantified as the number of CLS-B per square centimeter of breast WAT \( \text{CLS-B/cm}^2 \), was estimated, and the median (0.87 CLS-B/cm²) was considered the cutoff to differentiate between low and high CLS-B density.

As a quality control measure, adipocyte number was examined in a subset of participants \( n = 81 \) determined by counting the number of nuclei per 10X power fields. BMI was inversely associated with the number of adipocytes (Spearman rank correlation \( r = -0.47 \), 95% CI = \(-0.64, -0.29\), \( P < 0.001 \); Additional file 1: Supplementary Fig. 1A). CLS-B/cm² was also negatively correlated with the number of adipocytes, although not as strongly as for BMI (Spearman rank correlation \( r = -0.18 \), 95% CI = \(-0.40, 0.07\), \( P = 0.12 \); Additional file 1: Supplementary Fig. 1B).

**Statistical analysis**

Selected characteristics of the overall study population, by race and by detection of CLS-B, were summarized by mean and standard deviation (SD) for continuous variables and by frequencies and percentages for categorical variables. Logistic regression models were used to determine odds ratios (ORs) and 95% confidence intervals (CIs) for associations between race, BMI, and other potential factors with the detection of CLS-B (yes, no). Proportional odds models were used to examine associations between potential risk factors and CLS-B density (none, low, high). When examining associations...
with tumor characteristics, CLS-B status was treated as the exposure and logistic regression was used when the outcome was a binary tumor characteristic (ER status or lymph node status) and proportional odds models for tumor characteristics such as stage and grade, which are ordinal in nature. Potential confounders were selected for inclusion in multivariable models based on known associations in the literature and causal graphical analyses (directed acyclic graphs, DAGs).

For analyses examining associations between CLS-B detection and clinical outcomes, overall survival (OS) time and progression-free survival (PFS) time were calculated from the date of diagnosis until the date of breast cancer recurrence (for PFS only), death, last follow-up, or December 31, 2018, whichever came first. Breast cancer recurrence was determined via clinical data abstraction using REDCap. Vital status was determined by the Georgia Center for Cancer Statistics via routine linkage with the state mortality file, the National Death Index, and through active follow-up/other administrative sources. We excluded 15 non-Georgia residents lacking follow-up data and 8 with missing covariate information from survival analyses. Survival outcomes by any CLS-B detection were examined using Kaplan-Meier curves and the log-rank test as well as using age-adjusted and multivariable Cox proportional hazards regression to compute hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariable models adjusted for age at diagnosis (years), BMI (kg/m²), and smoking status (never, former, and current smokers) as these variables were determined to be associated with both CLS-B detection and clinical outcomes. The proportional hazards assumption was tested for each survival outcome using interaction terms between CLS-B exposure and the log of survival time. There was no violation for associations between CLS-B and overall survival. A violation was observed for the association between any CLS-B and PFS ($P = 0.02$); however, inspection of the log-log survival curves and Schoenfeld residuals revealed the violation was towards the end of the follow-up when few women remained under observation. Truncation at 6 years of follow-up did not materially change associations; thus, results including the full follow-up time are presented.

**Results**

**Study population**

The distribution of demographic and clinical characteristics at diagnosis is presented in Table 1. Mean age at breast cancer diagnosis was 56 years (SD 13.9; range 24–92) among African-American women and 55 years (SD 12.4 years; range 30–85) among White women. Approximately 63% were postmenopausal in both groups; however, African-American women were more likely to experience menopause at < 45 years of age (54% vs 38%) with a slightly higher proportion of surgical menopause (43% vs 38%). Mean BMI was 31.1 kg/m² (SD 7.6) among African-American women and 26.9 kg/m² (SD 6.5) among White women. African-American women were more likely than White women to have ER– tumors (30% vs 12%), to have poorly differentiated tumors (41% vs 22%), and to receive adjuvant chemotherapy (57% vs 39%).

**CLS-B detection and density by patient characteristics at diagnosis**

Detection of any CLS-B was similar between African-American (32%) and White (29%) patients with no evidence of an association between race and CLS-B in multivariable models adjusting for age at diagnosis and BMI (OR = 0.82, 95% CI = 0.49, 1.36) (Table 2). BMI was strongly and consistently associated with detection and density of CLS-B (Fig. 2d–f). As compared with under or ideal weight women, overweight women were more than twice as likely to have any detection of CLS-B (OR = 2.34, 95% CI = 1.17–4.70) and obese women more than four times as likely (OR = 4.73, 95% CI = 2.48–9.01), adjusting for age at diagnosis, race, and smoking status. As shown in Supplementary Table 1 in Additional file 1, BMI associations were similar for African-American women (overweight: OR = 2.60, 95% CI = 0.79–8.54; obese: OR = 5.28, 95% CI = 1.83–15.20) and White women (overweight: OR = 2.26, 95% CI = 0.93–5.50; obese: OR = 4.79, 95% CI = 2.01–11.50) with no evidence of effect modification by race ($P = 0.97$). Age at diagnosis was also positively associated with detection of any CLS-B (≥ 60 vs < 50 years: OR = 1.78, 95% CI = 0.99–3.21) and higher CLS-B density (OR = 1.85, 95% CI = 1.05–3.26). Parity was inversely associated with detection of any CLS-B with an OR of 0.49 (95% CI = 0.24–1.01) for parous women compared to nulliparous women. Current smoking was positively associated with detection of any CLS-B (OR = 2.13, 95% CI = 0.87–5.21) and higher CLS-B density (OR = 2.30, 95% CI = 0.99–5.32), compared to non-smokers; however, this pattern was not consistent across other CLS-B classification schemes likely due to the small number of current smokers ($n = 24$) in the study (Additional file 1: Supplementary Table 2). Associations for age at menarche, history of breastfeeding among parous women, menopausal status, hormone replacement therapy use among postmenopausal women, family history of breast cancer, diabetes, hypertension, and high cholesterol were null or too imprecise to make an inference.

**Tumor characteristics and clinical outcomes by CLS-B detection and density**

Detection of any CLS-B was not associated with any tumor characteristics examined including higher stage (OR = 0.95, 95% CI = 0.60–1.50), higher tumor grade
Table 1  Demographic and clinical characteristics of 342 women diagnosed with invasive breast cancer (stages I–III) by race, Emory University, 2007–2012

| Demographic characteristics | Total (N = 342) | African-American (N = 174) | White (N = 168) |
|-----------------------------|----------------|---------------------------|----------------|
| **Age at diagnosis (years)** |                |                           |                |
| Mean (SD)                   | 55.25 (13.20)  | 55.71 (13.91)             | 54.78 (12.43)  |
| **BMI (kg/m²), n (%)**      |                |                           |                |
| < 25                        | 126 (37.1)     | 40 (23.3)                 | 86 (51.2)      |
| 25 to < 30                  | 85 (25.0)      | 43 (25.0)                 | 42 (25.0)      |
| ≥ 30                        | 129 (37.9)     | 89 (51.7)                 | 40 (23.8)      |
| **Smoking status, n (%)**   |                |                           |                |
| Non-smoker                  | 225 (67.0)     | 111 (64.5)                | 114 (69.5)     |
| Past smoker                 | 87 (25.9)      | 44 (25.6)                 | 43 (26.2)      |
| Current smoker              | 24 (7.1)       | 17 (9.9)                  | 7 (4.3)        |
| **Age at menarche (years)** |                |                           |                |
| Mean (SD)                   | 12.68 (1.66)   | 12.59 (1.69)              | 12.77 (1.63)   |
| **Parity**                  |                |                           |                |
| Nulliparous                 | 44 (15.0)      | 19 (13.1)                 | 25 (16.9)      |
| Parous (1+ live births)     | 249 (85.0)     | 126 (86.9)                | 123 (83.1)     |
| **History of breastfeeding**, n (%) |          |                           |                |
| No                          | 75 (39.5)      | 38 (45.2)                 | 37 (34.9)      |
| Yes                         | 115 (60.5)     | 46 (54.8)                 | 69 (65.1)      |
| **Menopausal status, n (%)**|                |                           |                |
| Pre-/perimenopausal         | 117 (36.1)     | 59 (36.9)                 | 58 (35.4)      |
| Postmenopausal              | 207 (63.9)     | 101 (63.1)                | 106 (64.6)     |
| **Age at menopause**, n (%) |                |                           |                |
| < 45 years                  | 83 (45.4)      | 46 (53.5)                 | 37 (38.1)      |
| 45 to < 50 years            | 35 (19.1)      | 17 (19.8)                 | 18 (18.6)      |
| 50 to < 55 years            | 50 (27.3)      | 17 (19.8)                 | 33 (34.0)      |
| ≥ 55 years                  | 15 (8.2)       | 6 (7.0)                   | 9 (9.3)        |
| **History of hormone replacement therapy use**, n (%) |          |                           |                |
| No                          | 120 (63.8)     | 66 (75.0)                 | 54 (54.0)      |
| Yes                         | 68 (36.2)      | 22 (25.0)                 | 46 (46.0)      |
| **Family history of breast cancer among first-degree relatives, n (%)** |          |                           |                |
| No                          | 240 (73.6)     | 118 (74.2)                | 122 (73.1)     |
| Yes                         | 86 (26.4)      | 41 (25.8)                 | 45 (26.9)      |
| **Diabetes status, n (%)**  |                |                           |                |
| No                          | 298 (87.1)     | 140 (80.5)                | 158 (94.0)     |
| Yes                         | 44 (12.9)      | 34 (19.5)                 | 10 (6.0)       |
| **Hypertension status, n (%)** |            |                           |                |
| No                          | 200 (58.5)     | 82 (47.1)                 | 118 (70.2)     |
| Yes                         | 142 (41.5)     | 92 (52.9)                 | 50 (29.8)      |
| **High cholesterol status, n (%)** |          |                           |                |
| No                          | 286 (83.6)     | 141 (81.0)                | 145 (86.3)     |
Table 1  Demographic and clinical characteristics of 342 women diagnosed with invasive breast cancer (stages I–III) by race, Emory University, 2007–2012 (Continued)

| Clinical characteristics | Total (N = 342) | Race | African-American (N = 174) | White (N = 168) |
|--------------------------|----------------|------|---------------------------|----------------|
| Yes                      | 56 (16.4)      | 33 (19.0) | 23 (13.7)            |

**Clinical characteristics**

**ER status, n (%)**
- Positive: 267 (79.0)
- Negative: 71 (21.0)

**Stage, n (%)**
- Stage I: 163 (47.7)
- Stage II: 135 (39.5)
- Stage III: 44 (12.9)

**Tumor grade, n (%)**
- Well differentiated: 75 (22.9)
- Moderately differentiated: 150 (45.7)
- Poorly differentiated: 103 (31.4)

**Tumor size (cm), n (%)**
- ≤ 0.5: 7 (2.4)
- 0.5 to < 1: 43 (14.5)
- 1 to < 5: 222 (74.7)
- ≥ 5: 25 (8.4)

**Number of positive lymph nodes, n (%)**
- 0: 204 (60.6)
- ≥ 1: 107 (34.4)

**Chemotherapy, n (%)**
- No: 172 (52.4)
- Yes: 156 (47.6)

**Radiation, n (%)**
- No: 235 (71.4)
- Yes: 94 (28.6)

**Hormone therapy, n (%)**
- No: 109 (31.9)
- Yes: 233 (68.1)

*Abbreviations: BMI, body mass index; SD, standard deviation*

Note: Missing values were not included in the calculation of percentages

*Among parous women

*Among postmenopausal women only

(OR = 0.84, 95% CI = 0.53–1.34), ER− status (OR = 1.20, 95% CI = 0.65–2.19), or the presence of positive lymph nodes (OR = 1.05, 95% CI = 0.62–1.79), adjusting for age at diagnosis, race, and BMI in all models. The associations between CLS-B density and tumor characteristics were similar (Additional file 1: Supplementary Table 3).

Over a median of 8 years of follow-up, 46 breast cancer recurrences and 52 deaths (23 from breast cancer) occurred. The detection of any CLS-B was not associated with OS (HR = 1.02, 95% CI = 0.55–1.87) or PFS (HR = 0.99, 95% CI = 0.59–1.67), adjusting for age at diagnosis, BMI, and smoking status (Table 3; Fig. 3). Similar associations with OS and PFS were observed regardless of how CLS-B detection was determined (Additional file 1: Supplementary Table 4) or when CLS-B was further categorized by density (Table 3). When examined by race, we observed a difference in the direction of the association between any CLS-B and OS and PFS among African-American women (OS: adjusted HR = 1.18, 95% CI = 0.54–2.56; PFS: adjusted HR = 1.25, 95%...
### Table 2

Associations of potential risk factors with the detection and density of crown-like structures in breast adipose tissue (CLS-B) among 342 women diagnosed with invasive breast cancer (stages I–III) at Emory University between 2007 and 2012

| Characteristic                          | Any CLS-B \(\%\) | CLS-B Density (CLS-B/cm²) |
|----------------------------------------|------------------|--------------------------|
|                                        | \(N = 239\)     | \(N = 103\)              |
|                                        | \(N (%)\)       | \(N (%)\)                |
|                                        | Unadjusted \(\text{OR}^{a}\) (95% CI) | Adjusted \(\text{OR}^{a}\) (95% CI) | Unadjusted \(\text{OR}^{a}\) (95% CI) | Adjusted \(\text{OR}^{a}\) (95% CI) |
|                                        | N (%)           | N (%)                    | N (%)                        | N (%)                        |
| Race\(d\)                     |                  |                          |                              |                              |
| White                               | 120 (50)        | 48 (47)                  | 1.00 (--)                    | 1.00 (--)                    |
| African-American                     | 119 (50)        | 55 (53)                  | 1.16 (0.73–1.84)             | 0.82 (0.49–1.36)             |
| Age at diagnosis (years)\(d\)     |                  |                          |                              |                              |
| 25 to < 50                           | 86 (36)         | 27 (26)                  | 1.00 (--)                    | 1.00 (--)                    |
| 50 to < 60                           | 74 (31)         | 30 (29)                  | 1.29 (0.70–2.37)             | 1.20 (0.64–2.25)             |
| ≥ 60                                 | 79 (33)         | 46 (45)                  | 1.85 (1.05–3.26)             | 1.78 (0.99–3.21)             |
| BMI (kg/m²)\(d\)                   |                  |                          |                              |                              |
| < 25                                 | 106 (45)        | 20 (19)                  | 1.00 (--)                    | 1.00 (--)                    |
| 25 to < 30                           | 60 (25)         | 25 (24)                  | 2.21 (1.13–4.31)             | 2.34 (1.17–4.70)             |
| ≥ 30                                 | 71 (30)         | 58 (56)                  | 4.33 (2.40–7.81)             | 4.73 (2.48–9.01)             |
| Smoking status\(d\)                 |                  |                          |                              |                              |
| Non-smoker                           | 159 (67)        | 66 (66)                  | 1.00 (--)                    | 1.00 (--)                    |
| Past smoker                          | 64 (27)         | 23 (23)                  | 0.87 (0.50–1.51)             | 0.79 (0.44–1.41)             |
| Current smoker                       | 13 (6)          | 11 (11)                  | 2.04 (0.87–4.78)             | 2.13 (0.87–5.21)             |
| Age at menarche (years)\(d,e\)      |                  |                          |                              |                              |
| (years)                              | 127 (1.6)       | 127 (1.8)                | 0.98 (0.85–1.15)             | 1.06 (0.90–1.25)             |
| Parity\(d\)                          |                  |                          |                              |                              |
| Nulliparous                          | 28 (13)         | 16 (19)                  | 1.00 (--)                    | 1.00 (--)                    |
| Parous (1+ live births)              | 181 (87)        | 68 (81)                  | 0.66 (0.33–1.29)             | 0.49 (0.24–1.01)             |
| History of breastfeeding\(d,f\)     |                  |                          |                              |                              |
| No                                   | 52 (38)         | 23 (44)                  | 1.00 (--)                    | 1.00 (--)                    |
| Yes                                  | 86 (62)         | 29 (56)                  | 0.76 (0.40–1.46)             | 0.86 (0.44–1.70)             |
| Menopausal status\(d\)              |                  |                          |                              |                              |
| Pre-/perimenopausal                  | 89 (39)         | 28 (30)                  | 1.00 (--)                    | 1.00 (--)                    |
| Postmenopausal                       | 140 (61)        | 67 (71)                  | 1.52 (0.91–2.55)             | 1.41 (0.66–2.99)             |
| Age at menopause (years)\(f,g\)     |                  |                          |                              |                              |
| < 45                                 | 55 (44)         | 28 (49)                  | 1.00 (--)                    | 1.00 (--)                    |
| 45 to < 50                           | 25 (20)         | 10 (18)                  | 0.79 (0.33–1.86)             | 0.91 (0.38–2.21)             |
| 50 to < 55                           | 37 (29)         | 13 (23)                  | 0.69 (0.32–1.50)             | 0.74 (0.33–1.67)             |
| ≥ 55                                 | 9 (7)           | 6 (11)                   | 1.31 (0.42–4.05)             | 1.13 (0.34–3.71)             |
| Hormone replacement therapy use\(d,g\) |               |                          |                              |                              |
| No                                   | 77 (60)         | 43 (72)                  | 1.00 (--)                    | 1.00 (--)                    |
| Yes                                  | 51 (40)         | 17 (28)                  | 0.60 (0.31–1.16)             | 0.74 (0.37–1.50)             |
| Family history of breast cancer\(d\) |               |                          |                              |                              |
| No                                   | 165 (72)        | 75 (77)                  | 1.00 (--)                    | 1.00 (--)                    |
| Yes                                  | 63 (28)         | 23 (23)                  | 0.80 (0.46–1.39)             | 0.80 (0.45–1.40)             |
| Diabetes mellitus\(d\)              |                  |                          |                              |                              |
| No                                   | 210 (88)        | 88 (85)                  | 1.00 (--)                    | 1.00 (--)                    |
| Yes                                  | 29 (12)         | 15 (15)                  | 1.23 (0.63–2.42)             | 0.82 (0.39–1.73)             |

\(a\) Adjusted for age at diagnosis, menopausal status, and BMI.

\(b\) Adjusted for age at diagnosis, menopause status, and BMI.

\(c\) Adjusted for age at diagnosis and BMI.

\(d\) Results are shown relative to 12.7 (1.6) for race, 25 to < 50 for age at diagnosis, 25 to < 30 for BMI, 127 (1.6) for age at menarche, 1 for parity, and 0 for history of breastfeeding.

\(e\) Results are shown relative to 1.00 (--) for age at menarche, 1 for parity, and 0 for history of breastfeeding.

\(f\) Results are shown relative to 1.00 (--) for age at menarche, 1 for parity, and 0 for history of breastfeeding.

\(g\) Results are shown relative to 1.00 (--) for age at menarche, 1 for parity, and 0 for history of breastfeeding.
Table 2: Associations of potential risk factors with the detection and density of crown-like structures in breast adipose tissue (CLS-B) among 342 women diagnosed with invasive breast cancer (stages I–III) at Emory University between 2007 and 2012 (Continued)

| Characteristic | Any CLS-B<sup>a</sup> | CLS-B Density (CLS-B/cm<sup>2</sup>) |
|---------------|-----------------------|--------------------------------------|
|               | No  N = 239           | Yes N = 103                           |
|               | Unadjusted OR<sup>b</sup> (95% CI) | Adjusted OR<sup>b</sup> (95% CI) |
|               | N (%) | N (%) | N (%) | N (%) |
| Hypertension<sup>d</sup> | No 144 (60) | 56 (54) | 1.00 (--) | 1.00 (--) |
|               | Yes 95 (40) | 47 (46) | 1.27 (0.80–2.03) | 0.86 (0.50–1.49) |
| High cholesterol<sup>d</sup> | No 204 (85) | 82 (80) | 1.00 (--) | 1.00 (--) |
|               | Yes 35 (15) | 21 (20) | 1.49 (0.82–2.72) | 1.28 (0.68–2.42) |

Abbreviations: BMI: body mass index; CI: confidence interval; CLS-B: crown-like structures in the breast; OR: odds ratio

<sup>a</sup>Any CLS-B was defined as detection of ≥ 1 CLS-B with adipocyte encirclement ≥ 50% on the tissue section examined

<sup>b</sup>Estimated odds ratios using logistic regression models with any CLS-B (yes versus no) as the outcome

<sup>c</sup>Estimated odds ratios from proportional odds models; odds ratios represent the odds of increasing CLS-B (low or high CLS-B density versus no CLS-B; high CLS-B density versus none or low CLS-B density); score tests for the proportional odds assumption were not statistically significant (P > 0.05) for all models except for hormone replacement therapy use among postmenopausal women (P = 0.0032) which showed an inverse association for low CLS-B density (adjusted OR 0.28, 95% CI 0.09, 0.89) and a positive association for high CLS-B density (adjusted OR 2.17, 95% CI 0.75, max = 0.8) and specificity (min = 0.9, 0.95 ≤ mode ≤ 0.99, max = 1.0) and then reconstructed the data that would have been observed had the misclassified variable been correctly classified [29]. Models included the same covariates as the primary analysis and incorporated both random error and error due to misclassification in the simulation interval (SI) [29]. Bias-adjusted estimates were HR = 1.29 (95% SI = 0.60–2.89) for OS and HR = 1.17 (95% SI = 0.61–2.26) for PFS.

**Discussion**

The present study provides additional evidence that higher BMI is strongly associated with the detection and density of CLS-B [16–22] and provides new evidence that this association is similar in both White and African-American breast cancer patients. Race was not observed to be independently associated with detection or density of CLS-B. When we examined clinical outcomes over a median follow-up of 8 years, we found no difference in progression-free survival or overall survival by detection of CLS-B in unadjusted or adjusted models, contrary to two previous studies [19, 24]. However, estimates for these associations were imprecise, necessitating further research in larger study populations.

BMI is positively associated with CLS-B detection and density in numerous independent populations of breast cancer patients [16, 18, 20, 21, 24] and patients with benign breast disease [17]. The hypothesized biological mechanism relates higher BMI with adipocyte...
Table 3: Associations between crown-like structures in breast adipose tissue (CLS-B) and clinical outcomes among 319 women diagnosed with invasive breast cancer (stages I–III) at Emory University between 2007 and 2012 with follow-up data through December 31, 2018

| Exposure | Outcome                  | Category | Cases/person-years | Age-adjusted HR (95% CI) | Multivariable-adjusted HR (95% CI) |
|----------|--------------------------|----------|-------------------|--------------------------|-----------------------------------|
| Any CLS-B \( ^{ab} \) | Overall survival          | No       | 32/1635           | 1.00 (-- )              | 1.00 (-- )                        |
|          |                          | Yes      | 18/726            | 1.12 (0.63–1.99)        | 1.02 (0.55–1.87)                  |
| CLS-B density (CLS-B/cm\(^2\)) \( ^{b} \) |                          | None     | 32/1635           | 1.00 (--)                | 1.00 (--)                         |
|          |                          | Low (< 0.87) | 13/371     | 1.47 (0.77–2.82)        | 1.35 (0.68–2.68)                  |
|          |                          | High (≥ 0.87) | 5/355     | 0.69 (0.27–1.76)        | 0.63 (0.24–1.65)                  |
| Any CLS-B \( ^{ab} \) | Progression-free survival | No       | 47/1538           | 1.00 (-- )              | 1.00 (-- )                        |
|          |                          | Yes      | 24/704            | 1.05 (0.64–1.72)        | 0.99 (0.59–1.67)                  |
| CLS-B density (CLS-B/cm\(^2\)) \( ^{b} \) |                          | None     | 47/1538           | 1.00 (--)                | 1.00 (--)                         |
|          |                          | Low (< 0.87) | 14/362     | 1.15 (0.63–2.09)        | 1.08 (0.58–2.02)                  |
|          |                          | High (≥ 0.87) | 10/341    | 0.95 (0.48–1.88)        | 0.90 (0.45–1.81)                  |

Abbreviations: CI confidence interval, CLS-B crown-like structures in the breast, HR hazards ratio

\( ^{a} \)Any CLS-B was defined as detection of ≥ 1 CLS-B with adipocyte encirclement ≥ 50% on the tissue section examined

\( ^{b} \)Adjusted for age at diagnosis (years), body mass index (kg/m\(^2\)), and smoking status (never smoker, past smoker, current smoker)

Fig. 3: Kaplan-Meier curves comparing progression-free survival by detection of crown-like structures in breast adipose tissue (CLS-B)
hypertrophy and the subsequent formation of CLS-B [5, 13]. Previous studies have found positive correlations between BMI, adipocyte size, and CLS-B that support this hypothesis [13, 18, 20]. Similarly, we found a positive correlation between BMI and CLS-B detection and density, and our finding of an inverse association between BMI and adipocytes per unit area is compatible with prior data linking obesity to adipocyte enlargement [18].

The association between BMI and CLS-B appears consistent across racial/ethnic groups as evidenced by the present study comparing African-American and White patients as well as previous studies in Taiwanese [20] and Hispanic/Latina [22] breast cancer patient populations. We did not find evidence that race is associated with the detection or density of CLS-B. The similar proportion of CLS-B+ cases among African-American (32%) and White women (29%) despite the higher prevalence of obesity among African-American women (52% vs 24%) was driven by the lower proportion of CLS-B+ cases at every BMI level compared to White women (Fig. 2e and Supplementary Table 1). For example, 43% of obese African-American women were CLS-B+ while 50% were CLS-B+ among obese White women. This may be a reflection of race-dependent differences in body composition since African-Americans are known to have lower overall adiposity and percent body fat than Whites with the same BMI [30]. However, BMI was still strongly associated with CLS-B among African-Americans and when adjusted for in analyses, any positive association between race and CLS-B attenuated considerably. Differences in BMI or other patient factors could explain the previous finding of an association between Black race and CLS-B [24].

Data on the association between other risk factors and detection or density of CLS-B are sparse. In the present study, age ≥ 60 years at diagnosis was related to increased detection of CLS-B. Previous studies have found that patients with CLS-B tend to be older than those without CLS-B [16, 21, 22, 25] although all but one study estimate included the null [25]. Menopausal status has also been identified as related to CLS-B [16]. Current smoking was also associated with increased detection of CLS-B in our study although estimates were imprecise and depended on the definition used for detection of CLS-B (i.e., ≥ 50%, ≥ 75%, or ≥ 90% adipocyte encirclement). One previous study in Hispanic/Latina breast cancer patients also observed a positive association with current smoking; however, this study and the present study had few current smokers (n = 8 in the study by Greenlee et al. [22] and n = 24 in the present study). We also observed an inverse association between parity and CLS-B detection, which has not been previously reported. Future studies are needed to confirm whether the risk factors identified in the present study persist in other, larger study populations—ideally with pre-malignant breast tissue.

We did not observe an association between CLS-B detection or density with overall or progression-free survival, contrary to two previous studies that found CLS-B to be associated with worse clinical outcomes among breast cancer patients [19, 24]. There are several differences in the methods for CLS-B evaluation and outcome assessment between our study and the previous ones that could account for the discrepant results. In the study by Koru-Sengul et al., CLS was assessed using three different macrophage markers for detection (CD206, CD40, and CD163), and the observed association with worse overall survival was limited to CLS detected by CD40, an M1 macrophage marker that has been linked to pro-inflammatory conditions [24]. It is possible that different types of macrophages (M1 vs M2) have different effects on clinical outcomes that could be obscured by using a pan-macrophage marker like CD68, which was employed in the present study. In further contrast to our study, CLS was analyzed using banked tumor tissue in the study by Koru-Sengul et al., and it was unclear how far the evaluated adipose tissue was from the tumor. We evaluated adipose tissue remote from the tumor to avoid local effects of biopsy or inflammatory responses directed against the cancer cells as opposed to localized adipose tissue specifically. In the study by Iyengar et al., CLS-B was detected by CD68 staining, which was the same as the present study, but assessed time to distant recurrence in a group of patients that all developed metastatic disease, limiting generalizability of their study findings [19]. In contrast, we evaluated patients unrestricted to outcome. Another key difference was that the previous study by Iyengar et al. used five tissue sections per case to determine the presence of CLS-B (41% CLS-B+) while the present study used one (30% CLS-B+), which could have resulted in more frequent misclassification of CLS-B presence in our study. We attempted to adjust for this potential misclassification using a probabilistic bias analysis with the results suggesting a potential bias towards the null in our main analysis but with a large amount of uncertainty—as demonstrated by the wide simulation interval (PFS: HR = 1.17, 95% SI 0.61–2.26). This estimate was still closer to the null than the estimate found in the study by Iyengar et al. (HR = 1.83, 95% CI = 1.07–3.13), so the discrepant results are likely due to other differences between the two studies [19]. For instance, our study population included equal proportions of African-American and White women while the Iyengar et al. study included predominantly White women. Heterogeneity in associations by race such that CLS-B increases risk in one group but decreases risk in the other (potentially driven by differences in tumor subtype by...
race) could result in an overall null association. Larger studies with enough statistical power to stratify by both race and tumor subtype are needed to examine these potential differences and further understand how CLS-B might influence breast cancer prognosis. Finally, it seems possible that if BMI and CLS-B are etiologically related to breast cancer development, then index event bias—a type of collider bias commonly referred to as the “obesity paradox”—could lead to artificial associations between CLS-B and prognosis [31]. Given the limitations of the previous studies and the uncertainty surrounding the estimates in the present study (i.e., wide 95% CIs), it remains unclear whether CLS-B negatively influences breast cancer prognosis and further research is needed.

The present study has several strengths and limitations. Strengths include the large number of well-characterized breast cancer patients with detailed follow-up information. Additionally, sampling equal numbers of African-American and White breast cancer patients allowed for comparisons by race. However, because our study population only consisted of breast cancer patients, our results do not provide evidence for how CLS-B may affect the risk and development of breast cancer. To date, there has only been one study that has examined the association between CLS-B and the risk of breast cancer that was among patients with benign breast disease and found a higher risk for patients with abundant CLS-B [17]. Further, our study was limited to mastectomy specimens to enable sampling of breast fat remote from the cancers, which may have resulted in some differences in patients versus those treated with lumpectomy. Additionally, the use of only one tissue specimen per case to assess CLS-B could have resulted in lower detection. This potential misclassification is expected to be non-differential since pathologists were blinded to patient characteristics and clinical outcomes. However, accounting for this potential misclassification using probabilistic bias analysis resulted in only weak to moderate bias-adjusted HRs for both (HR = 1.17 for PFS; HR = 1.29 for OS). Finally, while most previous studies have used CD68 for detection of CLS-B [16, 19–21], it does not distinguish between types of macrophages (M1 vs M2) that could be associated with risk factors and prognosis differently.

Conclusions
This study further demonstrates the consistency and strength of association between BMI and detection and density of CLS-B in both African-American and White women diagnosed with breast cancer. Similar to previous studies, we did not find evidence that CLS-B was associated with tumor characteristics at diagnosis. However, in contrast to two previous investigations, we did not observe worse overall or progression-free survival among those with CLS-B present, raising questions related to differences in methodology in CLS-B assessment and whether CLS-B is in fact related to worse clinical outcomes.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13058-020-01308-4.

Additional file 1: Supplementary Methods for Assessment of Technical Sensitivity; Supplementary Fig. 1, Associations between the number of adipocytes and (A) body mass index (kg/m²) and (B) CLS-B/cm² in a subsample of breast cancer patients with breast adipose tissue obtained via mastectomy (n = 81). Supplementary Table 1, Associations between body mass index and detection of crown-like structures in the breast stratified by race among women diagnosed with invasive breast cancer (stage I-II), Emory University, 2007–2012; Supplementary Table 2, Associations of potential risk factors with detection of crown-like structures in the breast using different adipocyte encirclement cut-points for defining any CLS-B detection than the main analysis among women diagnosed with invasive breast cancer (stage I-II), Emory University, 2007–2012; Supplementary Table 3, Associations between detection and density of crown-like structures in breast adipose tissue (CLS-B) and tumor characteristics among women diagnosed with invasive breast cancer (stage I-II), Emory University, 2007–2012; Supplementary Table 4, Associations between the number of adipocytes and (A) body mass index (kg/m²) and (B) CLS-B/cm² in a subsample of breast cancer patients with breast adipose tissue obtained via mastectomy (n = 81). Supplementary Table 2.

Supplementary Table 1.

Supplementary Table 2.

Supplementary Table 3.

Supplementary Table 4.

Supplementary Table 5.

Description of data: Additional file 1.docx includes a section of supplementary methods followed by one supplementary figure and four supplementary tables.

Abbreviations
BMI: Body mass index; CI: Confidence interval; CLS-B: Crown-like structures in the breast; DAG: Directed acyclic graph; ER: Estrogen receptor; FFPE: Formalin-fixed paraffin-embedded; HR: Hazard ratio; H&E: Hematoxylin and eosin; IHC: Immunohistochemistry; OR: Odds ratio; OS: Overall survival; PBA: Probabilistic bias analysis; PFS: Progression-free survival; PR: Progesterone receptor; WAT: White adipose tissue; WHO: World Health Organization

Acknowledgements
We acknowledge the TREC Training Workshop RS5CA203650 (PI: Melinda Irwin) which facilitated the development of this work.

Authors’ contributions
LEM, MES, KG, and YL were involved in the study concept and design with LEM directing and coordinating all study aspects. LEM, JMK, and RY led immunohistochemical analyses of tissue samples. AMC, MES, UK, and RA assessed pathologic specimens. JH, JL, AMC, and LEM led the abstraction and review of clinical data. Data preparation and statistical analyses were done by MLM, AMC, YL, and JH, and all co-authors interpreted the data. MLM, AMC, and LEM wrote the manuscript, which was reviewed, revised, and improved by all authors. All authors read and approved the final manuscript.
Funding
Research was supported in part by funds from the Jimmy V Foundation (V2017-005) and the Cancer Tissue and Pathology Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. Study data were collected and managed using REDCap electronic data capture tools hosted at Emory University.

Availability of data and materials
The data used during the current study are available from the study PI on reasonable request and with approval of Emory's IRB.

Ethics approval and consent to participate
Informed consent was provided by women undergoing mastectomy at Emory University hospitals. This study was approved by the Institutional Review Board of Emory University (00100602).

Consent for publication
Not applicable.

Competing interests
KG reports receiving research funding from Merck, Novartis, Pfizer, and Roche for her role at Winship Cancer Institute/Emory University as site principal investigator for clinical trials and a one-time role on the advisory board to Eisai Lilly. No potential competing interests were disclosed by the other authors.

Author details
1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
2. Allegheny Health Network, Pittsburgh, PA, USA.
3. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
4. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
5. Winship Cancer Institute of Emory University, Atlanta, GA, USA.
6. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
7. Winship Cancer Institute of Emory University, Atlanta, GA, USA.
8. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
9. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
10. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
11. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.

Received: 17 February 2020 Accepted: 4 June 2020
Published online: 17 June 2020

References
1. Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34(35):4203–16.
2. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.
3. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14.
4. Potani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.
5. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66:297–309.
6. Key TJ, Appleby PN, Reeves Gk, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomark Prev. 2013;22(7):1319–24.
7. Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifiul N, Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomark Prev. 2013;22(7):1319–24.
8. Visscher M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22): 2131–5.
9. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhausser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(1): 3437–44.
10. Hursting SD, Diovanni J, Dannenberg AJ, Azad M, Leroith D, Demark-Wahnefried W, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila). 2012;5(11):1260–72.
11. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Fallico E, et al. Adipocytokine death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2547–55.
12. Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors. 2014(40):1–12.
13. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011;4(7):1021–9.
14. Engin AB, Engin A, Gonul Il. The effect of adipocyte-macrophage crosstalk in obesity-related breast cancer. J Mol Endocrinol. 2016;52(3):R201–R22.
15. Subbaramaiah K, Howe LR, Bharadwaj P, Du B, Gragavhi C, Yantis RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila). 2011;4(3):329–46.
16. Iyengar NM, Morris PG, Zhou XK, Gucalp A, Giri D, Harbus MD, et al. Menopause is a determinant of breast adipose inflammation. Cancer Prev Res (Phila). 2015;8(5):349–58.
17. Carter JM, Hoskin TL, Pena MA, Brahmbhatt R, Winham SJ, Frost MH, et al. Macrophagic “crown-like structures” are associated with an increased risk of breast cancer in benign breast disease. Cancer Prev Res (Phila). 2018;11(2):1313–9.
18. Vayss C, Homo J, Ganeil O, Fjeldheim F, Loffeord T, Schlichting E, et al. Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. NPJ Breast Cancer. 2017;3:19.
19. Iyengar NM, Zhou XK, Gucalp A, Morris PG, Howe LR, Giri DD, et al. Systemic correlates of white adipose tissue inflammation in early-stage breast cancer. Clin Cancer Res. 2016;22(20):2283–9.
20. Iyengar NM, Chen KC, Zhou XK, Giri DD, Falcone DJ, Winston LA, et al. Adiposity, inflammation, and breast cancer pathogenesis in Asian women. Cancer Prev Res (Phila). 2018;11(4):227–36.
21. Mullooly J, Yang HP, Falk RT, Nyante SJ, Cora R, Pfeiffer RM, et al. Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients. Breast Cancer Res. 2017;19(1)B.
22. Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, et al. Obesity-associated breast inflammation among Hispanic/Latina breast cancer patients. Cancer Prev Res (Phila). 2019;12(1):21–30.
23. Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, et al. Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal body mass index. Cancer Prev Res (Phila). 2017;10(4):255–43.
24. Kori-Sengul T, Santander AM, Xiao F, Sanchez LG, Jorda M, Gluck S, et al. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Res Treat. 2016;158(1):113–26.
25. Cha YJ, Kim ES, Koo JS. Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer. Breast Cancer Res Treat. 2018;170(1):15–25.
26. Harris PA, Taylor R, Thelike R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(4):377–81.
27. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;55:103-208.
28. World Health Organization. BMI classification [updated September 9, 2019. Accessed from: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 15 Nov 2019.
29. Fox MP, Lash TL, Greenland S. A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol. 2005; 34(6):1370–6.
30. Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM Jr. Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. Obes Res. 2006;14(3):262–75.
31. Park Y, Peterson LL, Colditz GA. The plausibility of obesity paradox in cancer-point. Cancer Res. 2018;78(8):1898–903.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.